Top Clinical Trials companies in South Korea by EBITDA
South Korea
# |
Name |
EBITDA |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
USD 1.62 M
|
Dec. 31, 2023 | USD 21.07 | 1.40% |
|
South Korea |
|
| 2 |
USD -8.55 M
|
Dec. 31, 2023 | USD 10.57 | -0.48% |
|
South Korea |
|
| 3 |
USD -13.90 M
|
Dec. 31, 2023 | USD 1.17 | -3.48% |
|
South Korea |
|
| 4 |
USD -23.06 M
|
Dec. 31, 2023 | USD 17.25 | 0.74% |
|
South Korea |
|
| 5 |
USD -25.04 M
|
Dec. 31, 2023 | USD 3.10 | -1.75% |
|
South Korea |
|
| 6 |
USD -31.39 M
|
Dec. 31, 2023 | USD 3.70 | 0.18% |
|
South Korea |
|
| 7 |
USD -48.92 M
|
Dec. 31, 2023 | USD 1.67 | -1.86% |
|
South Korea |
Frequently Asked Questions
-
Which Clinical Trials company in South Korea has the highest EBITDA ?
The Clinical Trials company in South Korea with the highest EBITDA is ABL Bio Inc. (KOSDAQ: 298380.KQ) at USD 1.62 M.
-
Which Clinical Trials company in South Korea has the lowest EBITDA ?
The Clinical Trials company in South Korea with the lowest EBITDA is GeneOne Life Science, Inc. (KSE: 011000.KS) at USD -48.92 M.
-
What are the top 10 Clinical Trials companies in South Korea by EBITDA ?
The top 10 Clinical Trials companies in South Korea by EBITDA are ABL Bio Inc., OliX Pharmaceuticals,Inc, Gencurix Inc., Oscotec Inc., MedPacto, Inc., Genexine, Inc. and GeneOne Life Science, Inc..
-
What are the bottom 10 Clinical Trials companies in South Korea by EBITDA ?
The bottom 10 Clinical Trials companies in South Korea by EBITDA are GeneOne Life Science, Inc., Genexine, Inc., MedPacto, Inc., Oscotec Inc., Gencurix Inc., OliX Pharmaceuticals,Inc and ABL Bio Inc..